BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 33040275)

  • 1. Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.
    Wang Y; Xu L; Liu Y; Hu Y; Shi Q; Jin L; Yang L; Wang P; Zhang K; Huang X; Ge Q; Lu J
    Int J Hematol; 2021 Feb; 113(2):231-242. PubMed ID: 33040275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis.
    Cuenca I; Alameda D; Sanchez-Vega B; Gomez-Sanchez D; Alignani D; Lasa M; Onecha E; Lecumberri R; Prosper F; Ocio EM; González ME; García de Coca A; De La Rubia J; Gironella M; Palomera L; Oriol A; Casanova M; Cabañas V; Taboada F; Pérez-Montaña A; De Arriba F; Puig N; Carreño-Tarragona G; Barrio S; Enrique de la Puerta J; Ramirez-Payer A; Krsnik I; Bargay JJ; Lahuerta JJ; Mateos MV; San-Miguel JF; Paiva B; Martinez-Lopez J
    Leukemia; 2021 Jan; 35(1):245-249. PubMed ID: 32203144
    [No Abstract]   [Full Text] [Related]  

  • 3. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis.
    Paiva B; Martinez-Lopez J; Corchete LA; Sanchez-Vega B; Rapado I; Puig N; Barrio S; Sanchez ML; Alignani D; Lasa M; García de Coca A; Pardal E; Oriol A; Garcia ME; Escalante F; González-López TJ; Palomera L; Alonso J; Prosper F; Orfao A; Vidriales MB; Mateos MV; Lahuerta JJ; Gutierrez NC; San Miguel JF
    Blood; 2016 Jun; 127(24):3035-9. PubMed ID: 27069257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases.
    Bianchi G; Kumar S
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1009-1026. PubMed ID: 33099420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Amyloidosis due to Low-Grade Lymphoma.
    Wechalekar AD; Chakraborty R; Lentzsch S
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1027-1039. PubMed ID: 33099421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AL amyloidosis with a localized B cell neoplasia.
    Stuhlmann-Laeisz C; Schönland SO; Hegenbart U; Oschlies I; Baumgart JV; Krüger S; Röcken C
    Virchows Arch; 2019 Mar; 474(3):353-363. PubMed ID: 30680453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
    Zhang C; Huang X; Li J
    Blood Rev; 2017 Jul; 31(4):261-270. PubMed ID: 28336182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development.
    Alameda D; Goicoechea I; Vicari M; Arriazu E; Nevone A; Rodriguez S; Lasa M; Puig N; Cedena MT; Alignani D; Garate S; Lara-Astiaso D; Vilas-Zornoza A; Sarvide S; Ocio EM; Lecumberri R; Garcia de Coca A; Labrador J; Gonzalez ME; Palomera L; Gironella M; Cabañas V; Casanova M; Oriol A; Krsnik I; Perez-Montaña A; de la Rubia J; de la Puerta JE; de Arriba F; Fazio VM; Martinez-Lopez J; Lahuerta JJ; Mateos MV; Odero MD; Prosper F; Weiner A; Amit I; Nuvolone M; San Miguel JF; Paiva B
    Blood; 2021 Oct; 138(17):1583-1589. PubMed ID: 34133718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity.
    Oliva L; Orfanelli U; Resnati M; Raimondi A; Orsi A; Milan E; Palladini G; Milani P; Cerruti F; Cascio P; Casarini S; Rognoni P; Touvier T; Marcatti M; Ciceri F; Mangiacavalli S; Corso A; Merlini G; Cenci S
    Blood; 2017 Apr; 129(15):2132-2142. PubMed ID: 28130214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis.
    Lisenko K; Schönland SO; Jauch A; Andrulis M; Röcken C; Ho AD; Goldschmidt H; Hegenbart U; Hundemer M
    Cancer Med; 2016 Jul; 5(7):1464-72. PubMed ID: 27109862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.
    Kriegsmann K; Dittrich T; Neuber B; Awwad MHS; Hegenbart U; Goldschmidt H; Hillengass J; Hose D; Seckinger A; Müller-Tidow C; Ho AD; Schönland S; Hundemer M
    Cytometry B Clin Cytom; 2018 Sep; 94(5):611-620. PubMed ID: 29577600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis.
    Zhou P; Hoffman J; Landau H; Hassoun H; Iyer L; Comenzo RL
    Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):49-58. PubMed ID: 22100494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New developments in diagnosis, risk assessment and management in systemic amyloidosis.
    Vaxman I; Dispenzieri A; Muchtar E; Gertz M
    Blood Rev; 2020 Mar; 40():100636. PubMed ID: 31706583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloidogenic light chains impair plasma cell survival.
    Pick M; Lebel E; Elgavish S; Benyamini H; Nevo Y; Hertz R; Bar-Tana J; Rognoni P; Merlini G; Gatt ME
    Haematologica; 2023 Dec; 108(12):3359-3371. PubMed ID: 37381778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel analysis of clonal diversification in blood B cell and bone marrow plasma cell clones in immunoglobulin light chain amyloidosis.
    Abraham RS; Manske MK; Zuckerman NS; Sohni A; Edelman H; Shahaf G; Timm MM; Dispenzieri A; Gertz MA; Mehr R
    J Clin Immunol; 2007 Jan; 27(1):69-87. PubMed ID: 17192818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers in Immunoglobulin Light Chain Amyloidosis.
    Kufová Z; Sevcikova T; Growkova K; Vojta P; Filipová J; Adam Z; Pour L; Penka M; Rysava R; Němec P; Brozova L; Vychytilova P; Jurczyszyn A; Grosicki S; Barchnicka A; Hajdúch M; Simicek M; Hájek R
    Klin Onkol; 2017; 30(Supplementum2):60-67. PubMed ID: 28903572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of clonal immunoglobulin λ light-chain gene rearrangements in AL amyloidosis using next-generation sequencing.
    Kimura K; Tsukamoto S; Miyazaki K; Kawajiri-Manako C; Ishii A; Rahmutulla B; Fukuyo M; Oshima-Hasegawa N; Mitsukawa S; Takeda Y; Mimura N; Takeuchi M; Ohwada C; Iseki T; Matsusaka K; Sanada M; Yokote K; Kaneda A; Ishida T; Suzuki K; Nakaseko C; Sakaida E
    Exp Hematol; 2021 Sep; 101-102():34-41.e4. PubMed ID: 34411686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and management of systemic light chain AL amyloidosis.
    Bhutani D; Lentzsch S
    Pharmacol Ther; 2020 Oct; 214():107612. PubMed ID: 32562825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous light chain amyloidosis with multiple myeloma: A concise review.
    Andrei M; Wang JC
    Hematol Oncol Stem Cell Ther; 2019 Jun; 12(2):71-81. PubMed ID: 30261180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapies for cardiac light chain amyloidosis: An update.
    Aimo A; Buda G; Fontana M; Barison A; Vergaro G; Emdin M; Merlini G
    Int J Cardiol; 2018 Nov; 271():152-160. PubMed ID: 30223349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.